Personalized Autoimmune Disease Prevention and Treatment System

A next-generation system for preventing and treating autoimmune diseases by targeting pathogenic age-associated B cells, leveraging advanced genomics, nanotechnology, and AI-driven analytics to provide personalized therapeutic interventions and early disease detection.

The original patent focused on treating autoimmune diseases by targeting pathogenic age-associated B cells. However, it had limitations in terms of personalized treatment and early disease detection. The new inventive concept addresses these limitations by introducing a system that integrates genetic markers, nanosensors, and AI-driven analytics to provide personalized risk profiles, targeted therapeutic interventions, and early disease detection.

The system comprises a database of genetic markers associated with pathogenic age-associated B cells, which enables identification of an individual's risk profile. The system then provides targeted therapeutic interventions to prevent disease onset. Additionally, the system includes a method for predicting autoimmune disease relapse by analyzing a subject's pathogenic age-associated B cell population dynamics and detecting aberrant cell expansion patterns indicative of relapse. A device for in vivo monitoring of pathogenic age-associated B cells, comprising a nanosensor that detects and quantifies the cells in real-time, enables early intervention and personalized treatment. The system also includes a composition for treating autoimmune diseases, comprising a combination of nucleic acids encoding human DEF6 and SWAP-70 proteins, and a nanoparticle delivery system that targets pathogenic age-associated B cells for selective elimination. Furthermore, the system features a computer-implemented method for identifying novel therapeutic targets for autoimmune diseases, comprising analyzing gene expression profiles of pathogenic age-associated B cells and identifying key regulators of cell expansion and function.

The new claims introduce a paradigm shift in autoimmune disease prevention and treatment by integrating advanced genomics, nanotechnology, and AI-driven analytics. The inventive concept is novel and non-obvious compared to the original patent, as it provides a comprehensive system for personalized risk profiling, early disease detection, and targeted therapeutic interventions.

Alternative embodiments of the system could include the use of different genetic markers, nanosensor designs, or AI-driven analytics. Variations could also include the integration of additional data sources, such as medical imaging or wearable devices, to further personalize therapeutic interventions.

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with applications in personalized medicine, autoimmune disease prevention and treatment, and targeted therapeutic interventions. The system could also be used in clinical settings for early disease detection and monitoring, providing a new standard of care for autoimmune disease patients.